| TA217 |
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine (TA217) |
|
-
-
dementia
Fast, easy summary view of NICE guidance on 'dementia'
-
-
-
Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease
This guidance replaces NICE technology appraisal guidance 111 issued in November 2006 (amended September 2007, August 2009).
The review and re-appraisal of donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer’s disease has resulted in a change in the guidance. Specifically:
- donepezil, galantamine and rivastigmine are now recommended as options for managing mild as well as moderate Alzheimer’s disease, and
- memantine is now recommended as an option for managing moderate Alzheimer’s disease for people who cannot take AChE inhibitors, and as an option for managing severe Alzheimer’s disease.
-
Other information
NICE Pathways
This guidance has been incorporated into the following NICE Pathways, along with other related guidance and products.
Visit the NICE Pathway: dementia
How this guidance was produced
Background information
This page was last updated: 18 May 2011
-
Guidance formats
- Web format
- Quick reference guide (PDF)
- Full Guidance (PDF)
- Patient version (MS Word)
- TA217 Donepezil, galantamine, rivastigmine a memantine ar gyfer clefyd Alzheimer: deall canllawiau NICE (fformat MS Word)
Alzheimer's disease - donepezil, galantamine, rivastigmine and memantine
Guideline for patients and carers (PDF)
-
Implementation tools and resources
See this guidance in practice
Patient
The summary of the key recommendations in the guidance written for patients, carers and those with little medical knowledge and may be used in local patient information leaflets.
Quick Reference Guide
The quick reference guide presents recommendations for health professionals
NICE Guidance
The published NICE clinical guidance, contains the recommendations for health professionals and NHS bodies.
Full Guidance
The published full clinical guidance for specialists with background, evidence, recommendations and methods used.
